Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;17(2):92-101.
doi: 10.17925/EE.2021.17.2.92. Epub 2021 Nov 17.

Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes

Dimitrios G Chatzis  1 , Konstantinos Kolokathis  2 , Kalliopi Magounaki  1 , Stefanos Chatzidakis  1 , Konstantinos Avramidis  2 , Marianna Leopoulou  3 , Theodoros P Angelopoulos  4 , John Doupis  2   4
Affiliations
Review

Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes

Dimitrios G Chatzis et al. touchREV Endocrinol. 2021 Nov.

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic disease with a constantly increasing prevalence worldwide. It is well established that T2DM affects both the macro- and microvasculature, and its presence is associated with a high risk of acute and chronic cardiovascular events. Traditionally, the management of T2DM has been mainly focused on the optimization of blood glucose levels with the use of antidiabetic medications. During recent years, however, an impressive accumulation of evidence has arisen from studies designed to explore the plausible effects of new antidiabetic drugs on cardiovascular outcomes in patients with diabetes. This review article aims to emphasize the findings of these studies and to highlight the substantial role of the newer classes of antidiabetic drugs in treating T2DM in a holistic, cardiorenal-metabolic approach, thus shifting the paradigm from the traditional, simplistic, glucose-lowering approach.

Keywords: Type 2 diabetes mellitus (T2DM); cardiorenal-metabolic; glucose-lowering; treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Dimitrios G Chatzis, Konstantinos Kolokathis, Kalliopi Magounaki, Stefanos Chatzidakis, Konstantinos Avramidis, Marianna Leopoulou, Theodoros P Angelopoulos and John Doupis have no financial or non-financial relationships or activities to declare in relation to this article.

Figures

Figure 1:
Figure 1:. The pathophysiological pathways of cardiorenal syndrome
See this image and copyright information in PMC

References

    1. Deepthi B, Sowjanya K, Lidiya B. et al. A modern review of diabetes mellitus: an annihilatory metabolic disorder. Journal of In Silico & In Vitro Pharmacology. 2017;3:1.
    1. Fan W. Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovasc Endocrinol. 2017;6:8–16. - PMC - PubMed
    1. Palau V, Riera M, Soler MJ. The reno-cardiovascular connection in the patient with diabetes mellitus: what’s new? Endocrinol Diabetes Nutr. 2017;64:237–40. - PubMed
    1. Koniari K, Nikolaou M, Paraskevaidis I, Parissis J. Therapeutic options for the management of the cardiorenal syndrome. Int J Nephrol. 2010;2011:194910. - PMC - PubMed
    1. De Rosa S, Arcidiacono B, Chiefari E. et al. Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links. Front Endocrinol (Lausanne). 2018;9:2. - PMC - PubMed

LinkOut - more resources